{"id":"sulphasalazine-ssz","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-8","effect":"Rash"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"<0.1","effect":"Agranulocytosis (rare)"},{"rate":"<0.1","effect":"Hepatotoxicity (rare)"}]},"_chembl":{"chemblId":"CHEMBL421","moleculeType":"Small molecule","molecularWeight":"398.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The 5-aminosalicylic acid (5-ASA) moiety acts as a topical anti-inflammatory agent in the intestinal mucosa, inhibiting prostaglandin and leukotriene synthesis and reducing neutrophil infiltration. The sulfapyridine component may also contribute to immunomodulatory effects. The drug is designed to deliver the active 5-ASA directly to the colon where it exerts its therapeutic benefit.","oneSentence":"Sulphasalazine is a prodrug that is cleaved by colonic bacteria into 5-aminosalicylic acid and sulfapyridine, with the 5-ASA component exerting local anti-inflammatory effects in the colon.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:10.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ulcerative colitis"},{"name":"Crohn's disease"},{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT02374021","phase":"PHASE4","title":"Treatments Against RA and Effect on FDG-PET/CT","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-07","conditions":"Arthritis, Rheumatoid","enrollment":159},{"nctId":"NCT01491815","phase":"PHASE4","title":"Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2012-12-14","conditions":"Rheumatoid Arthritis","enrollment":812},{"nctId":"NCT02466581","phase":"PHASE4","title":"Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2015-02-03","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT02930343","phase":"PHASE3","title":"Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy","status":"TERMINATED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2016-09","conditions":"Rheumatoid Arthritis","enrollment":136},{"nctId":"NCT02320630","phase":"NA","title":"Combination Therapy Prevents the Relapse of RA","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2015-10","conditions":"Recurrence (Disease Attribute)","enrollment":240},{"nctId":"NCT03411798","phase":"PHASE4","title":"Sequential Application of Yisaipu® and DMARDs in Treating Mild-to-Moderate AS","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2017-12-15","conditions":"Ankylosing Spondylitis","enrollment":76},{"nctId":"NCT00848354","phase":"PHASE4","title":"Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Rheumatoid Arthritis","enrollment":429},{"nctId":"NCT01015547","phase":"PHASE3","title":"Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2003-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT01659242","phase":"PHASE4","title":"Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study","status":"TERMINATED","sponsor":"Singapore General Hospital","startDate":"2012-07","conditions":"Rheumatoid Arthritis","enrollment":1},{"nctId":"NCT00259610","phase":"PHASE4","title":"Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2004-05","conditions":"Rheumatoid Arthritis","enrollment":755},{"nctId":"NCT00247962","phase":"PHASE4","title":"Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-12","conditions":"Ankylosing Spondylitis","enrollment":566},{"nctId":"NCT00764725","phase":"PHASE4","title":"Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":487}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":352,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"sulphasalazine (SSZ)","genericName":"sulphasalazine (SSZ)","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sulphasalazine is a prodrug that is cleaved by colonic bacteria into 5-aminosalicylic acid and sulfapyridine, with the 5-ASA component exerting local anti-inflammatory effects in the colon. Used for Ulcerative colitis, Crohn's disease, Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}